Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Xencor to co-develop IL-15 therapies with Genentech

Sandi Wong
February 7, 2019 6:58 PM UTC

Xencor Inc. (NASDAQ:XNCR) will receive $120 million up front in a deal to co-develop its IL-15 cytokine therapeutics, including XmAb24306, with Genentech Inc.

The partners will evaluate combinations of XmAb24306 with products from Genentech's oncology portfolio. Clinical data has suggested immune-stimulating cytokine therapies, including those based on IL-15, could increase the efficacy of checkpoint inhibitors (see "POC for Cytokines")...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Genentech Inc.

Roche

Xencor Inc.